<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884971</url>
  </required_header>
  <id_info>
    <org_study_id>CV-2021-29604</org_study_id>
    <nct_id>NCT04884971</nct_id>
  </id_info>
  <brief_title>Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study</brief_title>
  <official_title>Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial will evaluate the initial safety and feasibility of intestinal&#xD;
      microbiota transplantation (IMT) in patients with pulmonary arterial hypertension (PAH). This&#xD;
      trial will inform development of future trials in treatment of PAH. Active drug in capsule&#xD;
      form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors will be&#xD;
      administered to patients with PAH. This study will also allow for limited evaluation of&#xD;
      pharmacokinetics in terms of donor microbiota engraftment and pharmacodynamics in terms of&#xD;
      potential mechanisms. It will also allow for limited evaluation of cardiac endurance and&#xD;
      function prior to and after IMT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is a chronic disease characterized by pulmonary&#xD;
      vascular remodeling of precapillary pulmonary arteries resulting in obstruction, increased&#xD;
      pulmonary vascular resistance, right-sided cardiac failure, and ultimately death. Although&#xD;
      pharmacologic therapies have been developed, these modestly improve cardiac function and&#xD;
      primarily act to improve symptoms and quality of life; therefore, PAH remains a very lethal&#xD;
      disease. Perivascular lung inflammation drives these vascular changes in PAH. This&#xD;
      inflammatory profile could be driven by an imbalance of pro- and anti-inflammatory intestinal&#xD;
      microbial metabolites, cytokines, other mediators, and/or direct effects of circulating&#xD;
      bacteria all stemming from dysbiosis, gut-barrier dysfunction, and possibly, decreased&#xD;
      hepatic filtration. Because PAH is characterized by a microbiome distinct from healthy&#xD;
      controls, the investigators hypothesize that intestinal microbiota transplant (IMT) will help&#xD;
      to reduce severity of PAH and improve quality of life, and that the healthy microbiome may&#xD;
      exert these effects by decreasing inflammation. In this pilot clinical trial, the&#xD;
      investigators aim to test the safety and feasibility of IMT from healthy donors into patients&#xD;
      with PAH. Additionally, in the exploratory objectives, the investigators will obtain limited&#xD;
      data to study pharmacokinetics of IMT, including engraftment and stability of donor&#xD;
      intestinal microbiota, and pharmacodynamics to include circulating microbial products and&#xD;
      markers of inflammation. Proposed circulating markers that may be assessed include&#xD;
      interleukin-6, C-reactive protein, soluble CD14, lipopolysaccharide (LPS),&#xD;
      phenylacetylglutamine, trimethylamine N-oxide, intestinal fatty acid binding protein,&#xD;
      zonulin, claudin, short-chain fatty acids (SCFAs), tumor necrosis factor-α, interleukin-1β,&#xD;
      and transforming growth factor-β.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>In order to assess the safety of the trial, the frequency of adverse events will be reported. Outcome will be reported as the mean number of serious adverse events per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of IMT Compliance</measure>
    <time_frame>6 months</time_frame>
    <description>In order to assess the feasibility of the trial, the proportion of subjects taking 100% of the intestinal microbiota transplantation (IMT) doses per protocol will be reported. Outcome is reported as the percent of participants who consume 100% of IMT doses.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Microbiota Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the encapsulated microbiota intervention daily for seven days and will be subsequently monitored for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intestinal microbiota transplant (IMT)</intervention_name>
    <description>Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10^11 bacteria from a healthy donor are contained in each capsule.</description>
    <arm_group_label>Microbiota Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of pulmonary arterial hypertension (PAH)&#xD;
&#xD;
          -  On stable treatment for PAH for one month prior to enrollment&#xD;
&#xD;
          -  Able to swallow capsultes&#xD;
&#xD;
          -  Able to provide blood sample and fecal sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dysphagia to pills&#xD;
&#xD;
          -  Clinically active inflammatory bowel disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Life expectancy of &lt;6 months&#xD;
&#xD;
          -  Presence of ileostomy or colostomy&#xD;
&#xD;
          -  Taking immunosuppressants (calcineurin inhibitors, prednisone greater than or equal to&#xD;
             20mg/day, methotrexate, azathioprine, immunosuppressive biologics, JAK inhibitors)&#xD;
&#xD;
          -  Neurotropenia (an absolute neurotrophil count &lt; 0.5 x 10^9 cells/L)&#xD;
&#xD;
          -  History of solid organ or bone marrow transplant&#xD;
&#xD;
          -  Anticipated recurrent antibiotic use (participants with frequent urinary tract&#xD;
             infections or sinusitis)&#xD;
&#xD;
          -  History of severe anaphylactic food allergy&#xD;
&#xD;
          -  History of celiac disease&#xD;
&#xD;
          -  History of receiving cancer chemotherapy, immunotherapy, or radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daphne Moutsoglou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Division of Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thenappan Thenappan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Division of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Prins, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Division of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Weir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Division of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Khoruts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Division of Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daphne Moutsoglou, MD, PhD</last_name>
    <phone>612-899-6344</phone>
    <email>dmmoutso@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thenappan Thenappan, MD</last_name>
    <phone>612-899-2722</phone>
    <email>tthenapp@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

